Dissection of pik3ca aberration for cervical adenocarcinoma outcomes

Tony K.H. Chung; Graeme Doran; Tak Hong Cheung; So Fan Yim; Mei Yung Yu; Michael J. Worley; Kevin M. Elias; Aaron R. Thorner; Chandra Sekhar Pedamallu; Akinyemi I. Ojesina; Kei Man Lau; Matthew D. Ducar; Raymond R.Y. Wong; Vivian W. Wang; Anwesha Nag; Bruce M. Wollison; Audrey Dalgarno; Jacqueline H.S. Lee; Suet Ying Yeung; Lo Wong; Neil S. Horowitz; Michelle R. Davis; Shuk On A. Leung; Yi Mu; Samuel C. Mok; Paul K.S. Chan; Michael S. Lawrence; Christopher P. Crum; Rossa W.K. Chiu; Ross S. Berkowitz; Yick Fu Wong

doi:10.3390/cancers13133218

Dissection of pik3ca aberration for cervical adenocarcinoma outcomes

Tony K.H. Chung, Graeme Doran, Tak Hong Cheung, So Fan Yim, Mei Yung Yu, Michael J. Worley, Kevin M. Elias, Aaron R. Thorner, Chandra Sekhar Pedamallu, Akinyemi I. Ojesina, Kei Man Lau, Matthew D. Ducar, Raymond R.Y. Wong, Vivian W. Wang, Anwesha Nag, Bruce M. Wollison, Audrey Dalgarno, Jacqueline H.S. Lee, Suet Ying Yeung, Lo WongNeil S. Horowitz, Michelle R. Davis, Shuk On A. Leung, Yi Mu, Samuel C. Mok, Paul K.S. Chan, Michael S. Lawrence, Christopher P. Crum, Rossa W.K. Chiu, Ross S. Berkowitz, Yick Fu Wong

Gynecological Oncology & Reproductive Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient’s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women’s cancer.

Original language	English (US)
Article number	3218
Journal	Cancers
Volume	13
Issue number	13
DOIs	https://doi.org/10.3390/cancers13133218
State	Published - Jul 1 2021

Keywords

Cervical adenocarcinoma
Mutation
PIK3CA

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3390/cancers13133218

Cite this

Chung, T. K. H., Doran, G., Cheung, T. H., Yim, S. F., Yu, M. Y., Worley, M. J., Elias, K. M., Thorner, A. R., Pedamallu, C. S., Ojesina, A. I., Lau, K. M., Ducar, M. D., Wong, R. R. Y., Wang, V. W., Nag, A., Wollison, B. M., Dalgarno, A., Lee, J. H. S., Yeung, S. Y., ... Wong, Y. F. (2021). Dissection of pik3ca aberration for cervical adenocarcinoma outcomes. Cancers, 13(13), Article 3218. https://doi.org/10.3390/cancers13133218

Chung, TKH, Doran, G, Cheung, TH, Yim, SF, Yu, MY, Worley, MJ, Elias, KM, Thorner, AR, Pedamallu, CS, Ojesina, AI, Lau, KM, Ducar, MD, Wong, RRY, Wang, VW, Nag, A, Wollison, BM, Dalgarno, A, Lee, JHS, Yeung, SY, Wong, L, Horowitz, NS, Davis, MR, Leung, SOA, Mu, Y, Mok, SC, Chan, PKS, Lawrence, MS, Crum, CP, Chiu, RWK, Berkowitz, RS & Wong, YF 2021, 'Dissection of pik3ca aberration for cervical adenocarcinoma outcomes', Cancers, vol. 13, no. 13, 3218. https://doi.org/10.3390/cancers13133218

@article{62905ef5a3b24260a43ee1685f390826,

title = "Dissection of pik3ca aberration for cervical adenocarcinoma outcomes",

abstract = "Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient{\textquoteright}s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women{\textquoteright}s cancer.",

keywords = "Cervical adenocarcinoma, Mutation, PIK3CA",

author = "Chung, {Tony K.H.} and Graeme Doran and Cheung, {Tak Hong} and Yim, {So Fan} and Yu, {Mei Yung} and Worley, {Michael J.} and Elias, {Kevin M.} and Thorner, {Aaron R.} and Pedamallu, {Chandra Sekhar} and Ojesina, {Akinyemi I.} and Lau, {Kei Man} and Ducar, {Matthew D.} and Wong, {Raymond R.Y.} and Wang, {Vivian W.} and Anwesha Nag and Wollison, {Bruce M.} and Audrey Dalgarno and Lee, {Jacqueline H.S.} and Yeung, {Suet Ying} and Lo Wong and Horowitz, {Neil S.} and Davis, {Michelle R.} and Leung, {Shuk On A.} and Yi Mu and Mok, {Samuel C.} and Chan, {Paul K.S.} and Lawrence, {Michael S.} and Crum, {Christopher P.} and Chiu, {Rossa W.K.} and Berkowitz, {Ross S.} and Wong, {Yick Fu}",

note = "Funding Information: Funding: This work was supported by the Hong Kong Research Grant Council (Reference Number 14101315). Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = jul,

day = "1",

doi = "10.3390/cancers13133218",

language = "English (US)",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "13",

}

TY - JOUR

T1 - Dissection of pik3ca aberration for cervical adenocarcinoma outcomes

AU - Chung, Tony K.H.

AU - Doran, Graeme

AU - Cheung, Tak Hong

AU - Yim, So Fan

AU - Yu, Mei Yung

AU - Worley, Michael J.

AU - Elias, Kevin M.

AU - Thorner, Aaron R.

AU - Pedamallu, Chandra Sekhar

AU - Ojesina, Akinyemi I.

AU - Lau, Kei Man

AU - Ducar, Matthew D.

AU - Wong, Raymond R.Y.

AU - Wang, Vivian W.

AU - Nag, Anwesha

AU - Wollison, Bruce M.

AU - Dalgarno, Audrey

AU - Lee, Jacqueline H.S.

AU - Yeung, Suet Ying

AU - Wong, Lo

AU - Horowitz, Neil S.

AU - Davis, Michelle R.

AU - Leung, Shuk On A.

AU - Mu, Yi

AU - Mok, Samuel C.

AU - Chan, Paul K.S.

AU - Lawrence, Michael S.

AU - Crum, Christopher P.

AU - Chiu, Rossa W.K.

AU - Berkowitz, Ross S.

AU - Wong, Yick Fu

N1 - Funding Information: Funding: This work was supported by the Hong Kong Research Grant Council (Reference Number 14101315). Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021/7/1

Y1 - 2021/7/1

N2 - Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient’s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women’s cancer.

AB - Personalized treatment of genetically stratified subgroups has the potential to improve outcomes in many malignant tumors. This study distills clinically meaningful prognostic/predictive genomic marker for cervical adenocarcinoma using signature genomic aberrations and single-point nonsynonymous mutation-specific droplet digital PCR (ddPCR). Mutations in PIK3CA E542K, E545K, or H1047R were detected in 41.7% of tumors. PIK3CA mutation detected in the patient’s circulating DNA collected before treatment or during follow-up was significantly associated with decreased progression-free survival or overall survival. PIK3CA mutation in the circulating DNA during follow-up after treatment predicted recurrence with 100% sensitivity and 64.29% specificity. It is the first indication of the predictive power of PIK3CA mutations in cervical adenocarcinoma. The work contributes to the development of liquid biopsies for follow up surveillance and a possibility of tailoring management of this particular women’s cancer.

KW - Cervical adenocarcinoma

KW - Mutation

KW - PIK3CA

UR - http://www.scopus.com/inward/record.url?scp=85108696152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108696152&partnerID=8YFLogxK

U2 - 10.3390/cancers13133218

DO - 10.3390/cancers13133218

M3 - Article

C2 - 34203201

AN - SCOPUS:85108696152

SN - 2072-6694

VL - 13

JO - Cancers

JF - Cancers

IS - 13

M1 - 3218

ER -

Dissection of pik3ca aberration for cervical adenocarcinoma outcomes

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this